We describe a detailed protocol for the generation of human induced pluripotent stem cell-derived brain organoids and their use in modeling mitochondrial diseases.
Mitochondrial diseases represent the largest class of inborn errors of metabolism and are currently incurable. These diseases cause neurodevelopmental defects whose underlying mechanisms remain to be elucidated. A major roadblock is the lack of effective models recapitulating the early-onset neuronal impairment seen in the patients. Advances in the technology of induced pluripotent stem cells (iPSCs) enable the generation of three-dimensional (3D) brain organoids that can be used to investigate the impact of diseases on the development and organization of the nervous system. Researchers, including these authors, have recently introduced human brain organoids to model mitochondrial disorders. This paper reports a detailed protocol for the robust generation of human iPSC-derived brain organoids and their use in mitochondrial bioenergetic profiling and imaging analyses. These experiments will allow the use of brain organoids to investigate metabolic and developmental dysfunctions and may provide crucial information to dissect the neuronal pathology of mitochondrial diseases.
Mitochondrial diseases represent the largest class of inborn errors of metabolism1. They are caused by genetic mutations disrupting different mitochondrial processes, including oxidative phosphorylation (OXPHOS)2, respiratory chain assembly, mitochondrial dynamics, and mitochondrial DNA transcription or replication3. Tissues with energy requirements are particularly affected by mitochondrial dysfunction4. Accordingly, patients with mitochondrial diseases typically develop early-onset neurological manifestations.
There are currently no treatments available for children affected with mitochondrial diseases5. A major hindrance for drug development of mitochondrial diseases is the lack of effective models recapitulating the human disease course6. Several of the currently studied animal models do not exhibit the neurological defects present in the patients7. Hence, the mechanisms underlying the neuronal pathology of mitochondrial diseases are still not fully understood.
Recent studies generated iPSCs from patients affected by mitochondrial diseases and used these cells to obtain patient-specific neuronal cells. For example, genetic defects associated with the mitochondrial disease, Leigh syndrome, have been found to cause aberrations in cellular bioenergetics8,9, protein synthesis10, and calcium homeostasis9,11. These reports provided important mechanistic clues on the neuronal impairment occurring in mitochondrial diseases, paving the way for drug discovery for these incurable diseases12.
Two-dimensional (2D) cultures, however, do not enable the investigation of the architectural complexity and regional organization of 3D organs13. To this end, the use of 3D brain organoids derived from patient-specific iPSCs14 may allow researchers to gain additional important information and thereby help to dissect how mitochondrial diseases impact the development and function of the nervous system15. Studies employing iPSC-derived brain organoids to investigate mitochondrial diseases are beginning to uncover the neurodevelopmental components of mitochondrial diseases.
Spinal cord organoids carrying mutations associated with the mitochondrial disease, mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS), showed defective neurogenesis and delayed motor neuron differentiation16. Cortical organoids derived from patients with the mitochondrial disease, Leigh syndrome, showed reduced size, defects in neural epithelial bud generation, and loss of cortical architecture17. Brain organoids from Leigh syndrome patients showed that the disease defects initiate at the level of neural progenitor cells, which cannot commit to mitochondrial metabolism, causing aberrant neuronal branching and morphogenesis18. Thus, neural progenitors may represent a cellular therapeutic target for mitochondrial diseases, and strategies promoting their mitochondrial function may support the functional development of the nervous system.
The use of brain organoids might help uncover the neurodevelopmental components of mitochondrial diseases. Mitochondrial diseases are mainly considered as early-onset neurodegeneration5. However, neurodevelopmental defects are also present in patients affected by mitochondrial diseases, including developmental delay and cognitive impairment19. Patient-specific brain organoids may help address these aspects and elucidate how mitochondrial diseases may impact human brain development. Mitochondrial dysfunction could also play a pathogenetic role in other more common neurological diseases, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease4. Hence, elucidating the impact of mitochondrial defects in neurodevelopment using brain organoids might also be instrumental for the study of those diseases. This paper describes a detailed protocol for generating reproducible brain organoids that can be used for conducting disease modeling of mitochondrial diseases.
NOTE: The use of human iPSCs may require an ethical approval. iPSCs used in this study were derived from healthy control individuals following local ethical approval (#2019-681). All cell culture procedures must be performed under a sterile cell culture hood, carefully disinfecting all reagents and consumables before transferring under the hood. Human iPSCs used for differentiation should have a passage number below 50 to avoid potential genomic aberrations that may occur upon extensive culture. The pluripotent state of the cells should be validated before organoid generation, for example, by monitoring the expression of pluripotency-associated markers such as NANOG or OCT4. Mycoplasma tests should be conducted weekly to ensure mycoplasma-free cultures.
1. Generation of brain organoids
2. Immunostaining of brain organoids
3. Bioenergetic profiling of brain organoids
The protocol described here facilitates the robust generation of round organoids (Figure 1A). The generated organoids contain mature neurons that can be visualized using protein markers specific for axons (SMI312) and dendrites (microtubule-associated protein 2 (MAP2)) (Figure 1B). Mature organoids contain not only neuronal cells (MAP2-positive) but also glial cells (e.g., positive for the astrocyte marker S100 calcium-binding protein B (S100ß)) (Figure 1B).
By analyzing sliced brain organoids using confocal microscopy, it is possible to identify and monitor the detailed distribution and organization of different cell types and cellular structures. This could provide new insight into how mitochondrial diseases might affect nervous system development. For example, it is possible to monitor neuronal axons (SMI312-positive) and dendrites (MAP2-positive) (Figure 2A) or the mutual occurrence of neuronal cells (MAP2-positive) and glial cells (S100ß-positive) (Figure 2A). Confocal images may also help to investigate in more detail the distribution and organization of neural progenitors ((sex determining region Y) box-2 (SOX2)-positive) with respect to neurons (beta-III tubulin (TUJ1)-positive) (Figure 2B). Finally, brain organoids can be stained for mitochondria-specific markers (such as the outer mitochondrial membrane protein, translocase of outer membrane 20 kDa subunit (TOM20)) (Figure 2C).
The described protocol enables researchers to perform bioenergetic profiling of brain organoids. Using this procedure, it is possible to measure both mitochondrial metabolism using the oxygen consumption rate (OCR) (Figure 2D) and the glycolytic metabolism using the extracellular acidification rate (ECAR) (Figure 2E). Bioenergetic profiling allows monitoring how cells may modify their OCR and ECAR profiles in response to a sequential administration of mitochondrial inhibitors.
First, the ATP synthase inhibitor, oligomycin, can be applied. Oligomycin causes a drop in the OCR profile (Figure 2D), and therefore, identifies the OCR needed for ATP production. Upon oligomycin treatment, there may also be a compensatory increase in ECAR (Figure 2E), suggesting that the cells can upregulate glycolysis to prevent the metabolic stress caused by the reduction in mitochondrial metabolism. The subsequent double application of the proton ionophore, carbonyl cyanide-p-trifluoromethoxyphenylhydrazon (FCCP), causes the loss of the mitochondrial membrane potential. As the oxygen molecules are now free to move, this causes a rapid increase in OCR (Figure 2D).
These changes in the OCR profile identify the maximal respiration capacity of the cells. The final administration of rotenone plus antimycin A causes a block of the electron transport, and therefore, a steep decrease in OCR (Figure 2D). ECAR may show fluctuation after treatment with FCCP and rotenone plus antimycin A (Figure 2E), depending on the residual glycolytic capacity of the cells. The OCR and ECAR profiles may be dramatically altered in brain organoids derived from mitochondrial patients.
Figure 1: Generation of brain organoids from human iPSCs. (A) Schematic representation of the protocol used to produce brain organoids with corresponding transmission images. Day 0 corresponds to the dissociation of iPSCs and seeding in a 96-well plate with V-bottom using CDMI supplemented with a ROCK inhibitor, a WNT inhibitor, and SB431542. At day 18, neurospheres are transferred from the 96-well plates to 100 mm cell culture dishes with CDMII supplemented with N2. From this point onwards, the cultures are positioned on an orbital shaker. At day 35, the medium is switched from CDMII to CDMIII, which also contains a dissolved matrix component (Table 1). From day 70 onwards, CDMIII is switched to CDMIV supplemented with B27. A representative neurosphere image was taken at day 12 using a microscope camera with 10x magnification. An early organoid image was taken at day 22 using a microscope camera at 4x magnification. A mature organoid image was taken at day 40 using a microscope camera with 4x magnification. (B) The overall structure and cellular organization of brain organoids can be visualized using wide-field microscopy. Representative stitched wide-field images are shown to visualize the relationships between dendrites (MAP2-positive) and axons (SMI312-positive), and between neuronal cells (MAP2-positive) and presumed astrocytes (S100ß-positive). The cells were counterstained with Hoechst to reveal the nuclei. All images were taken using 78 day-old brain organoids. The right column shows the overlay of three channels (merge). Scale bars = 500 µm. Abbreviations: iPSC = induced pluripotent stem cell; CDM = Cortical Differentiation Medium; ROCK = Rho kinase; MAP2 = microtubule-associated protein 2; S100ß= S100 calcium-binding protein B. Please click here to view a larger version of this figure.
Figure 2: Visualization and bioenergetic profiling of brain organoids for mitochondrial disease modeling. The detailed organization and architecture of organoids can be analyzed using confocal microscopy. All images were taken using 78 day-old brain organoids and counterstained with Hoechst to reveal the nuclei. The right column shows the overlay of three channels (merge). Scale bars = 50 µm. (A) Representative extended-focus projections (44-48 optical planes, 0.6 µm each) addressing the interplay between dendrites (MAP2-positive, arrowheads) and axons (SMI312-positive, arrows), and between neuronal cells (MAP2-positive, arrowheads) and presumed astrocytes (S100ß-positive, arrows). (B) Representative extended-focus projections (14-31 optical planes, 0.6 µm each) showing the distribution of neurons (TUJ1-positive, arrowheads) with respect to neural progenitors (SOX2-positive, arrows). (C) Representative extended-focus projections (20 optical planes, 0.6 µm each) showing the distribution within neurons (TUJ1-positive, arrowheads) of mitochondria (visualized using antibodies against the outer mitochondrial membrane protein TOM20, arrows). (D) Mitochondrial respiration of brain organoids can be monitored based on the profile of the OCR after sequential administration of different mitochondrial inhibitors (see text for details). (E) Glycolytic activity of brain organoids can be monitored based on the ECAR upon sequential administration of mitochondrial inhibitors (see text for details). For bioenergetic profiling, approximately 10-15 brain organoids were dissociated to obtain enough cells for replating onto the 96-well microplate. The bars indicate the SEMs based on the results obtained in two independent experiments. Abbreviations: MAP2 = microtubule-associated protein 2; S100ß = S100 calcium-binding protein B; TUJ1 = beta-III tubulin; SOX2 = (sex determining region Y) box-2; TOM20 = translocase of outer membrane 20 kDa subunit; OCR = oxygen consumption rate; ECAR = extracellular acidification rate; Oligom. = oligomycin; FCCP = carbonyl cyanide-p-trifluoromethoxyphenylhydrazon; R = rotenone; AntA = Antimycin A; SEMs = standard error of means. Please click here to view a larger version of this figure.
Media Composition | |||
CDMI (Day 0-18) | Final conc. | ||
Glasgow-MEM | Gibco | 11710-035 | [1:1] |
Knockout Serum Replacement (KSR) | Gibco | 10828010 | 20% |
MEM-NEAA (MEM non-essential amino acid solution) | Gibco | 11140-050 | 0.1 mM |
Sodium Pyruvate | Gibco | 11360070 | 1 mM |
2-mercaptethanol | Gibco | 31350-010 | 0.1 mM |
Penicillin and streptomycin | Gibco | 15140-122 | 100 U/mL and 100 μg/mL |
CDMII (Day 18-35) | Final conc. | ||
DMEM/F12 | Gibco | 31330038 | [1:1] |
Glutamax | Gibco | 35050-061 | 2 mM |
N-2 Supplement (100x) | Gibco | 17502-048 | 1% |
Chemically Defined Lipid Concentrate | Gibco | 11905031 | 1% |
Penicillin and streptomycin | Gibco | 15140-122 | 100 U/mL and 100 μg/mL |
CDMIII (Day 35-70) | Final conc. | ||
DMEM/F12 | Gibco | 31330038 | [1:1] |
Glutamax | Gibco | 35050-061 | 2 mM |
N-2 Supplement (100x) | Gibco | 17502-048 | 1% |
Chemically Defined Lipid Concentrate | Gibco | 11905031 | 1% |
Penicillin and streptomycin | Gibco | 15140-122 | 100 U/mL and 100 μg/mL |
Fetal Bovine Serum (FBS) | Gibco | 10270-106 | 10% |
Heparin | Merck | H3149-25KU | 5 μg/mL |
Matrigel | Corning | 356231 | 1% |
CDMIV(Day 70+) | Final conc. | ||
DMEM/F12 | Gibco | 31330038 | [1:1] |
Glutamax | Gibco | 35050-061 | 2 mM |
N-2 Supplement (100x) | Gibco | 17502-048 | 1% |
Chemically Defined Lipid Concentrate | Gibco | 11905031 | 1% |
Penicillin and streptomycin | Gibco | 15140-122 | 100 U/mL and 100 μg/mL |
Fetal Bovine Serum (FBS) | Gibco | 10270-106 | 10% |
Heparin | Merck | H3149-25KU | 5 μg/mL |
Matrigel | Corning | 356231 | 2% |
B-27 supplement with Vitamin A 50x | Gibco | 17504044 | 2% |
Neuronal Medium | Final conc. | ||
DMEM/F12 | Gibco | 31330038 | [1:1] |
N-2 supplement | Gibco | 17502048 | [1x] |
B-27 supplement with vitamin A 50x | Gibco | 17504044 | [1x] |
L-Ascorbic acid | Sigma Aldrich | A92902 | [200 µM] |
db-cAMP (dibutyryl cyclic adenosine monophosphate) | Sigma Aldrich | D0627 | 500 µM |
BDNF (brain-derived neutrotrophic factor) | MACS Miltenyi | 130-093-811 | [10 ng/mL] |
GDNF (glial cell line-derived neurotrophic factor) | MACS Miltenyi | 130-096-290 | [10 ng/mL] |
Human TGF-β3 (transforming growth factor-beta3) | MACS Miltenyi | 130-094-007 | [1 ng/mL] |
Assay Medium | Final conc. | ||
Seahorse XF DMEM medium | Seahorse Bioscience | 103680-100 | 500 mL |
Sodium Pyruvate | Gibco | 11360070 | 1 mM |
L-Glutamine | Lonza | BEBP17-605E | 2 mM |
Glucose | Sigma Aldrich | 50-99-7 | 10 mM |
Blocking Solution | Final conc. | ||
PBS-Tween | [1:1] 0.1% Tween | ||
Donkey Serum | Sigma Aldrich | D9663 | 10% |
Triton-X | Merck | X100-5ML | 1% |
Table 1: Details of media and solutions used for organoid generation.
Initialization | Baseline (X3) | Oligomycin Injection (X3) | FCCP Injection (X3) | FCCP Injection (X3) | Anti A + Rot Injection (X3) |
Calibrate | Mix | Mix | Mix | Mix | Mix |
(04:00) | (04:00) | (04:00) | (04:00) | (04:00) | |
Equilibrate (12:00) | Wait | Wait | Wait | Wait | Wait |
(02:00) | (02:00) | (02:00) | (02:00) | (02:00) | |
Measure (03:00) | Measure (03:00) | Measure (03:00) | Measure | Measure (03:00) | |
(03:00) |
Table 2: Protocol setup for bioenergetic profiling. Description of the steps and their length in minutes using the Seahorse Wave Desktop software. Abbreviations: FCCP = carbonyl cyanide-p-trifluoromethoxyphenylhydrazon; Rot = rotenone; Anti A = Antimycin A.
This paper describes the reproducible generation of human iPSC-derived brain organoids and their use for mitochondrial disease modeling. The protocol described here is modified based on a previously published work20. One major advantage of the present protocol is that it does not require the manual embedding of each organoid into a scaffolding matrix. In fact, the matrix solution is simply dissolved into the cell culture medium. Moreover, there is no need to employ expensive bioreactors, as organoids can be cultured in standard tissue culture 6-well plates positioned onto an orbital shaker inside the incubator. This procedure also enables the parallel cultivation of several plates containing different organoids derived from various individual lines, thereby increasing the throughput of the experiments and allowing the monitoring of potential differences emerging in the growth profiles of different organoids. We tested this protocol using different iPSCs derived from healthy controls and individuals affected by mitochondrial diseases, with consistent results.
For mitochondrial disease modeling, it is essential to use different markers to visualize the morphology and organization of the mitochondrial network. This procedure enables the investigation of whether mitochondrial number, morphology, or distribution might be altered in brain organoids derived from patients with mitochondrial diseases. The presence and organization of neural progenitors within the brain organoids could be of crucial importance for modeling mitochondrial disorders. We recently discovered that mutations causing the mitochondrial disease, Leigh syndrome, disrupt the cellular architecture and distribution of neural progenitor cells within patient-derived brain organoids18.
For performing bioenergetic profiling, we have adapted a method that was previously described for assessing the bioenergetics of pluripotent stem cells21. A recent protocol described how to carry out bioenergetic profiling of organoids derived from mouse small intestine, human colon, and colorectal tumors22. However, those organoids are quite small compared to brain organoids, and therefore, a different protocol, such as the one reported here, is needed for brain organoids. We recently employed this protocol for assessing the bioenergetic profile of human brain organoids carrying mutations in the surfeit locus protein 1 gene (SURF1) that causes the severe mitochondrial disease, Leigh syndrome18. We found that the OCR profile is particularly affected in Leigh syndrome organoids, as shown by a significant decrease in the basal OCR level, the ATP production rate, and the maximal respiration rate18.
In conclusion, we present here a detailed protocol for the robust generation of human brain organoids and describe how to perform experiments that would be important for the investigation of the disease mechanisms underlying mitochondrial diseases. Human brain organoids may also be of critical importance for elucidating the mitochondrial diversity in the human brain and its role in human health and diseases23. It is important to clarify that brain organoids generated with currently available protocols, including the one described here, still bear limitations. These include, for example, the lack of vascularization and the absence of microglia population24. These aspects need to be taken into consideration to interpret the results correctly.
For example, the lack of vasculature and microglia could limit compensatory mechanisms that may be in place in vivo. Patient-derived brain organoids might thus exhibit defects that are stronger than the ones observed in patients17,18. Moreover, despite a general reproducibility of this protocol20, line-to-line heterogeneity can be observed. To this end, when performing disease modeling studies, it is always important to systematically quantify the uniformity of control and patient organoids by assessing the patterns of morphology (size, layer) and the distribution of molecular markers across different organoids.
Finally, it is not possible to generate brain organoids from a single iPSC, limiting the feasibility of large-scale genetic screening with CRISPR/Cas9. Given the pace of research, it is likely that some of the current limitations of the protocol described here will soon be overcome. Optimized protocols will become available. These 3D models of mitochondrial diseases will hopefully enable the eventual discovery of implementable therapies for mitochondrial diseases, which are detrimental, and for incurable diseases with highly unmet medical needs.
The authors have nothing to disclose.
We thank Miriam Bünning for technical support. We acknowledge support from the Deutsche Forschungsgemeinschaft (DFG) (PR1527/5-1 to A.P.), Spark and Berlin Institute of Health (BIH) (BIH Validation Funds to A.P.), the United Mitochondrial Disease Foundation (UMDF) (Leigh Syndrome International Consortium Grant to A.P.), University Hospital Duesseldorf (Forschungskommission UKD to A.P.), and the German Federal Ministry of Education and Research (BMBF) (e:Bio young investigator grant AZ 031L0211 to A.P.).Work in the laboratory of C.R.R. was supported by the DFG (FOR 2795 "Synapses under stress", Ro 2327/13-1).
2-mercaptoethanol | Gibco | 31350-010 | |
Affinity Designer | Serif (Europe) Ltd | Layout software; Vector graphics editor | |
Alexa Fluor 488 donkey anti-guinea pig | Sigma Aldrich | SAB4600033-250UL | 1:300 |
Alexa Fluor 488 donkey anti-mouse | Thermo Fisher Scientific | A-31571 | 1:300 |
Antimycin A | Sigma Aldrich | 1397-94-0 | |
Anti-β-Tubulin III (TUJ-1) | Sigma Aldrich | T8578 | 1:2000 |
Argon Laser | Melles Griot | Any other Laser, e.g., diode lasers emitting 488 is fine, too | |
Ascorbic acid | Sigma | A92902 | |
B-27 with Vitamin A | Gibco | 17504044 | |
Bacto Agar | Becton Dickinson | 3% in PBS, store solution at -20 °C | |
BDNF | Miltenyi Biotec | 130-093-0811 | |
cAMP | Sigma | D0627 | |
Cell Star cell culture 6 well plate | Greiner-Bio-One | 657160 | |
Chemically Defined Lipid Concentrate | Gibco | 11905031 | |
Confocal laser scanning microscope C1 | Nikon Microscope Solutions | Modular confocal microscope system | |
Corning Matrigel Growth Factor Reduced (GFR) Basement membrane matrix, Phenol Red-free, LDEV-free | Corning | 356231 | Matrix component |
CyQUANT Cell Proliferation Assay Kit | Thermo Fisher | C7026 | |
DMEM/F12 | ThermoFisher | 31330038 | |
DMSO | Sigma | D2660-100ML | |
Donkey anti-goat Cy3 | Merck Millipore | AP180C | 1:300 |
Donkey anti-mouse Cy3 | Merck Millipore | AP192C | 1:300 |
Donkey anti-rabbit Cy3 | Merck Millipore | AP182C | 1:300 |
DPBS | Gibco | 14190250 | |
DS-Q1Mc camera | Nikon Microscope Solutions | ||
Eclipse 90i upright widefield microscope | Nikon Microscope Solutions | ||
Eclipse E 600FN upright microscope | Nikon Microscope Solutions | ||
Eclipse Ts2 Inverted Microscope | Nikon Microsope Solutions | ||
EZ-C1 Silver Version 3.91 | Nikon Microscope Solutions | Imaging software for confocal microscope | |
FCCP | Sigma Aldrich | 370-86-5 | |
Fetal Bovine Serum | Gibco | 10270-106 | |
GDNF | Miltenyi Biotec | 130-096-291 | |
Glasgow MEM | Gibco | 11710-035 | |
Glass Pasteur pipette | Brand | 747715 | Inverted |
Glutamax | Gibco | 35050-061 | |
Helium-Neon Laser | Melles Griot | Every other Laser, e.g., diode lasers emitting 594 is fine, too | |
Heparin | Merck | H3149-25KU | |
HERACell 240i CO2 Incubator | Thermo Scientific | 51026331 | |
Hoechst 33342 | Invitrogen | H3570 | 1:2500 |
Image J 1.53c | Wayne Rasband National Institute of Health | Image processing Software | |
Injekt Solo 10 mL/ Luer | Braun | 4606108V | |
Knockout Serum Replacement | Gibco | 10828010 | |
Laser (407 nm) | Coherent | Any other Laser, e.g., diode lasers emitting 407 is fine, too | |
Map2 | Synaptic Systems | No. 188004 | 1:1000 |
Maxisafe 2030i | |||
MEM NEAA | Gibco | 11140-050 | |
mTeSR Plus | Stemcell Technology | 85850 | iPSC medium |
Multifuge X3R Centrifuge | Thermo Scientific | 10325804 | |
MycoAlert Mycoplasma Detection Kit | Lonza | # LT07-218 | |
N2 Supplement | Gibco | 17502-048 | |
Needle for single usage (23G x 1” TW) | Neoject | 10016 | |
NIS-Elements Aadvanced Research 3.2 | Nikon | Imaging software | |
Oligomycin A | Sigma Aldrich | 75351 | |
Orbital Shaker Heidolph Unimax 1010 | Heidolph | 543-12310-00 | |
PAP Pen | Sigma | Z377821-1EA | To draw hydrophobic barrier on slides. |
Papain Dissociation System kit | Worthington | LK003150 | |
Paraformaldehyde | Merck | 818715 | 4% in PBS, store solution at -20 °C |
Pasteur pipette 7mL | VWR | 612-1681 | Graduated up to 3 mL |
Penicillin-Streptomycin | Gibco | 15140-122 | |
Plan Apo VC 20x / 0.75 air DIC N2 ∞/0.17 WD 1.0 | Nikon Microscope Solutions | Dry Microscope Objective | |
Plan Apo VC 60x / 1.40 oil DIC N2 ∞/0.17 WD 0.13 | Nikon Microscope Solutions | Oil Immersion Microscope Objective | |
Polystyrene Petri dish (100 mm) | Greiner Bio-One | 664161 | |
Polystyrene round-bottom tube with cell-strainer cap (5 mL) | Falcon | 352235 | |
Potassium chloride | Roth | 6781.1 | |
ProLong Glass Antifade Moutant | Invitrogen | P36980 | |
Qualitative filter paper | VWR | 516-0813 | |
Rock Inhibitior | Merck | SCM075 | |
Rotenone | Sigma | 83-794 | |
S100β | Abcam | Ab11178 | 1:600 |
SB-431542 | Cayman Chemical Company | 13031 | |
Scalpel blades | Heinz Herenz Hamburq | 1110918 | |
SMI312 | Biolegend | 837904 | 1:500 |
Sodium bicarbonate | Merck/Sigma | 31437-1kg-M | |
Sodium chloride | Roth | 3957 | |
Sodium dihydrogen phosphate | Applichem | 131965 | |
Sodium Pyruvate | Gibco | 11360070 | |
SOX2 | Santa Cruz Biotechnology | Sc-17320 | 1:100 |
StemPro Accutase Cell Dissociation Reagent | Gibco/StemPro | A1110501 | Reagent A |
Super Glue Gel | UHU | 63261 | adhesive gel |
SuperFrost Plus | VWR | 631-0108 | |
Syringe for single usage (1 mL) | BD Plastipak | 300015 | |
TB2 Thermoblock | Biometra | ||
TC Plate 24 Well | Sarstedt | 83.3922 | |
TC Plate 6 Well | Sarstedt | 83.392 | |
TGFbeta3 | Miltenyi Biotec | 130-094-007 | |
Tissue Culture Hood | ThermoFisher | 51032711 | |
TOM20 | Santa Cruz Biotechnology | SC-11415 | 1:200 |
Triton-X | Merck | X100-5ML | |
UltraPure 0.5M EDTA | Invitrogen | 15575020 | |
Vibratome Microm HM 650 V | Thermo Scientific | Production terminated, any other adjustable microtome is fine, too. | |
Vibratome Wilkinson Classic Razor Blade | Wilkinson Sword | 70517470 | |
Whatman Benchkote | Merck/Sigma | 28418852 | |
Wnt Antagonist I | EMD Millipore Corp | 3378738 | |
XF 96 extracellular flux analyser | Seahorse Bioscience | 100737-101 | |
XF Assay DMEM Medium | Seahorse Bioscience | 103680-100 | |
XF Calibrant Solution | Seahorse Bioscience | 100840-000 | |
XFe96 FluxPak (96-well microplate) | Seahorse Bioscience | 102416-100 |